Amphastar Pharmaceuticals, Inc.

Informe acción NasdaqGS:AMPH

Capitalización de mercado: US$2.0b

Salud financiera de hoja de balance de Amphastar Pharmaceuticals

Salud financiera controles de criterios 3/6

Amphastar Pharmaceuticals tiene un patrimonio de accionistas total de $639.4M y una deuda total de $589.4M, lo que sitúa su ratio deuda-patrimonio en 92.2%. Sus activos y pasivos totales son $1.5B y $873.5M respectivamente. El BAIT de Amphastar Pharmaceuticals es de $199.7M, por lo que su ratio de cobertura de intereses es de 9.2. Tiene efectivo e inversiones a corto plazo que ascienden a $256.8M.

Información clave

92.2%

Ratio deuda-patrimonio

US$589.40m

Deuda

Ratio de cobertura de intereses9.2x
EfectivoUS$256.81m
PatrimonioUS$639.42m
Total pasivoUS$873.49m
Activos totalesUS$1.51b

Actualizaciones recientes sobre salud financiera

Recent updates

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Mar 27
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Mar 04

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Jan 04
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Dec 20
Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Dec 03
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

Sep 18
Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

Sep 03
An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Aug 17
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

Jun 02
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

May 11
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Mar 02
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Feb 07
Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Jan 24
Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Nov 02
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Amphastar: A Pharmaceutical Growth Stock

Oct 06

Amphastar wins FDA approval for Epinephrine pre-filled syringes

Aug 16

Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond

Aug 08

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Jul 24
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Amphastar generic vasopressin for increasing blood pressure gets FDA approval

Jul 19

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Jun 10
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio

May 13

I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease

Apr 23
I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Feb 13
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Amphastar Pharma: A Well-Run, Diversified Mid Cap

Jan 26

Should You Be Adding Amphastar Pharmaceuticals (NASDAQ:AMPH) To Your Watchlist Today?

Jan 08
Should You Be Adding Amphastar Pharmaceuticals (NASDAQ:AMPH) To Your Watchlist Today?

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($489.6M) de AMPH superan a sus pasivos a corto plazo ($225.4M).

Pasivo a largo plazo: Los activos a corto plazo ($489.6M) de AMPH no cubren sus pasivos a largo plazo ($648.1M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de AMPH (52%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de AMPH ha crecido de 13.5% a 92.2% en los últimos 5 años.

Cobertura de la deuda: La deuda de AMPH está bien cubierta por el flujo de caja operativo (31.1%).

Cobertura de intereses: Los pagos de intereses de la deuda de AMPH están bien cubiertos por el BAIT (9.2x cobertura).


Hoja de balance


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target